论文部分内容阅读
目的探讨抗凋亡蛋白survivin在肺腺癌组织中的表达及其与紫杉醇(PTX)化疗疗效的关系。方法应用免疫组化方法,对40例接受PTX化疗的肺腺癌患者survivin表达水平进行检测,分析其与PTX化疗疗效的关系。结果survivin在肺腺癌患者阳性率为65%(26/40);survivin表达阳性率在化疗有效组(CR 4例,PR 6例)、稳定组(23例)、进展组(7例)分别为50.0%(5/10)、65.2%(15/23)、85.7%(6/7),有效组与进展组之间有显著性差异(P<0.05);survivin阳性组化疗有效率为12.0%(3/25),明显低于survivin表达阴性组46.7%(7/15)(P<0.05)。结论survivin表达水平与PTX对肺腺癌化疗疗效呈显著负相关,survivin高表达者PTX化疗效果差,survivin可能作为一项预测PTX疗效、筛选肺腺癌化疗药物、指导制定合理治疗方案的新指标。
Objective To investigate the expression of anti-apoptotic protein survivin in lung adenocarcinoma and its relationship with the efficacy of paclitaxel (PTX) chemotherapy. Methods The expression of survivin in 40 patients with lung adenocarcinoma receiving PTX chemotherapy was detected by immunohistochemistry. The relationship between PTX chemotherapy and PTX chemotherapy was analyzed. Results The positive rate of survivin in lung adenocarcinoma was 65% (26/40). The positive rate of survivin was significantly higher in chemotherapy-effective group (CR 4 cases, PR 6 cases), stable group (23 cases) and progression group (7 cases) (50.0%), 65.2% (15/23) and 85.7% (6/7) respectively. There was a significant difference between the effective group and the advanced group (P <0.05). The effective rate of chemotherapy in survivin positive group was 12.0 % (3/25), which was significantly lower than 46.7% (7/15) in survivin negative group (P <0.05). Conclusion The expression of survivin is significantly negatively correlated with the therapeutic effect of PTX on the chemotherapy of lung adenocarcinoma. The high expression of survivin is associated with poor efficacy of PTX chemotherapy. Survivin may be used as a new index to predict the efficacy of PTX, screen chemotherapeutic drugs of lung adenocarcinoma and guide the development of rational treatment .